The FDA has announced updates to the prescribing information and safety labelling for all prescription opioid medicines, including both immediate-release (IR) and extended-release/long-acting (ER/LA) formulations. These updates include the addition of a new warning regarding the risk of opioid-induced hyperalgesia (OIH), cautionary notes on . . .
Sign Up or Log In as a healthcare professional to read the full article.